pancreatic cancer or biliary tract cancer
Conditions
Interventions
S-1 chemotherapy is conducted. S-1 80mg/m2/day is orally administered twice daily every monday, wednesday,friday and sunday for 6 weeks.
Sponsors
Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)unresectable or recurrent pancreatic cancer or biliary tract cancer(include locally advanced or recurence) 2)standard chemotyerapy cannot be performed for some reason 3)sufficient function of important organs WBC: >=2,000/mm3 and <=12,000/mm3 Neut:>=1,000/mm3 Platelet: >=75,000/mm3 Hem: >=8.0g/dl sT.bil: <=3.0mg/dl AST, ALT: <= 150IU/L Ccr: >=30 ml/min/body 4)oral intake 5)written informed consent *ECOG P.S.:anything is OK
Exclusion criteria
Exclusion criteria: 1)administration contraindication of TS-1 2)with clinically important infection 3)with sever heart failure 4)with interstitial pneumonia or pulmonary fibrosis 5)with sever complication(Intestinal paralysis, Ileus, uncontrollable diabetes mellitus, Renal failure, Liver failure etc) 6)massive ascites fluid or pleural effusion 7)repetitive blood infusion for gastrointestinal hemorrhage 8)with mental disorder receving treatment or needing treatment 9)administered Flucytosine, Phenytoin, Warfarin potassium 10)pregnant women or lactating women or women who like be pregnant and willing to get pregnant, men who want his partner to be pregnant 11)doctor's decision not to be registered to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment completed rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Progeression-free survival Adverse events Time to treatment failure | — |
Countries
Japan
Contacts
Public ContactMinoru Kitago
Department of Surgery, Keio University School of Medicine Department of Surgery
Outcome results
None listed